HD-PLC-ALLIANCE
21.1.2020 02:02:05 CET | Business Wire | Press release
In Japan, the High-definition Power Line Communication (HD-PLC ) technology has been mostly used in PLC adapters and communication equipment so far. One major reason was the interpretation of the “Ministerial Order to Provide Technical Standards for Electrical Appliances and Materials” which applied to the integration of HD-PLC into home electric appliances and housing equipment. Recently, the efforts of the involved parties have been rewarded by the Notice issued on December 25, 2019 by the Ministry of Economy, Trade and Industry (METI) that partially revised the interpretation of the Ministerial Order. HD-PLC can now be integrated in home appliances and housing equipment.
The main advantages of HD-PLC over wireless technologies include an easy setup of communication networks, a high level of security, and low power consumption. Additionally, HD-PLC can be used on power lines, coaxial cables, telephone lines, and other existing lines which not only enables the deployment of networks in in-house environments such as homes, buildings, and factories, but also the deployment of large outdoor networks covering areas of some square kilometers.
Furthermore, HD-PLC is expected to play an important role in underground facilities and radio-shielded spaces in buildings and houses where wireless reception is bad, while users expects high-speed, low-latency applications be provided by next-generation 5G networks. HD-PLC can play a unique role by working in conjunction with 5G, Wi-Fi, Bluetooth, and other wireless technologies to enhance the quality of service of networks. The ministerial order revision has opened the way for consumers to buy stationary home appliances with build-in HD-PLC technology, making easy to build networks by simply connecting the equipment to an electric outlet. This will provide a new solution for interconnecting electric appliances.
Yoshiyuki Miyabe, Senior Managing Executive Officer of Panasonic Corporation, the founding company of the HD-PLC Alliance, sent us a message: “Panasonic’s fourth-generation HD-PLC technology has already been approved as the IEEE 1901a Standard. We are excited by the huge opportunities that the ministerial order revision has opened to make HD-PLC one of the most innovative core technologies in the age of IoT. Panasonic will take advantage of these opportunities to integrate the technology in many of our products and solutions, working toward its further development and expansion and offering new values to our customers.”
HD-PLC Alliance will continue to promote the use of HD-PLC in electric appliances and to provide certification of HD-PLC built-in machinery and equipment ensuring communication compatibility. Simultaneously, we will keep making efforts to improve the certification environment. With the motto “HD-PLC takes up the challenge of becoming the IoT solution that connects people’s living, industry, and the community,” we will keep contributing toward establishing universal standards and promoting wider use of HD-PLC compatible products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
